Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
Primary Objective:
To determine if dasatinib, an inhibitor of the Src family kinases, can prevent the nuclear translocation of the epidermal growth factor receptor (EGFR) in Stage I-III, nuclear EGFR positive, triple negative breast cancers (TNBC).
Secondary Objectives:
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria for nEGFR testing:
Patients must have histologically or cytologically confirmed Stage I-III triple negative breast cancer
No prior therapy for current breast cancer
Meet criteria for neoadjuvant chemotherapy or primary breast surgery, as determined by primary oncologist and surgeon
Inclusion Criteria for study therapy:
Exclusion Criteria:
Primary purpose
Allocation
Interventional model
Masking
5 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal